VIP — vasoactive intestinal peptide — is one of the more genuinely interesting molecules to reach the wellness market, because the underlying biology is real and well characterized. It is an endogenous human neuropeptide with documented jobs in vasodilation, immune signaling and the body clock. Its synthetic form, aviptadil, has been put through actual clinical trials in serious lung disease. And yet the version most people encounter — a compounded nasal spray sold for “chronic inflammatory response syndrome” and mold illness — sits almost entirely outside that evidence. Three different stories share one name, and separating them is the whole point of this page.
What VIP actually is
VIP is a 28-amino-acid neuropeptide found throughout the human nervous system, gut and immune tissue. It is not a designer research chemical — like LL-37, it is a real, endogenous signaling molecule your body already makes. It works by binding a family of G-protein-coupled receptors — VPAC1, VPAC2 and PAC1 — which it shares with the closely related peptide PACAP. The pharmacology and tissue distribution of these receptors have been formally catalogued by IUPHAR, and they explain VIP’s reach: smooth-muscle relaxation (hence vasodilation and bronchodilation), secretion, and a broad set of immune and neural effects.[1] On the immune side specifically, VIP is best understood as an anti-inflammatory, tolerance-promoting neuropeptide with what one major review calls “pleiotropic immune functions” — it dampens pro-inflammatory signaling and shifts immune cells toward a regulatory phenotype.[2] It also has a documented circadian role: VPAC2 signaling in the brain’s master clock helps keep the daily rhythm coherent. In short, the biology is legitimate and deep.
The pulmonary story: vasodilation and aviptadil
Because VIP relaxes vascular smooth muscle and is abundant in the lung, the obvious therapeutic idea was pulmonary vascular disease. An early, widely cited study proposed VIP as a new drug for primary pulmonary hypertension, reporting that inhaled VIP improved hemodynamics and symptoms in a small, open-label group of patients.[3] That result was genuinely intriguing — but it was small, uncontrolled, and, importantly, was not subsequently confirmed by robust randomized trials into an approved pulmonary-hypertension therapy. It is the honest template for how VIP tends to behave in the clinic: a strong mechanistic rationale and an encouraging early signal that later, better-controlled work does not reliably reproduce.
Aviptadil in COVID-19: studied properly, and mostly negative
The most rigorous human data on synthetic VIP come from the COVID-19 pandemic, when aviptadil (synthetic VIP) was tested in patients with severe respiratory failure on the rationale that VIP protects the alveolar cells that the virus attacks. A 60-day randomized controlled trial in critically ill COVID-19 patients reported a survival and recovery signal in favor of aviptadil, which generated considerable interest.[4] But the decisive test was TESICO, a large, multicenter, placebo-controlled NIH trial of IV aviptadil in COVID-19–associated hypoxemic respiratory failure. It did not find that aviptadil meaningfully improved recovery; the drug failed to demonstrate the benefit the earlier, smaller study had suggested.[5] This is the pattern that matters: when synthetic VIP was finally subjected to a properly powered, placebo-controlled trial, the encouraging early signal did not hold up. “Was studied in a serious trial” is not the same as “works” — and here the best trial was, on its primary reading, negative.
The nasal-VIP “mold / CIRS” protocol
Almost none of the above describes how VIP is actually sold to consumers. In the wellness world, VIP is best known as a compounded intranasal spray promoted within the “chronic inflammatory response syndrome” (CIRS) framework associated with Ritchie Shoemaker — a proposed mold- and biotoxin-illness protocol in which nasal VIP is presented as a final “repair” step. It is important to be plain here: this use has essentially no controlled clinical evidence behind it. There are no randomized trials showing that intranasal VIP treats mold illness, “biotoxin” illness, or the constellation of symptoms grouped under CIRS — and CIRS itself is not an accepted diagnostic entity in mainstream medicine. The genuine immune and vasodilatory pharmacology of VIP[1][2] is being used as a plausibility argument for an application that has never been tested the way the pulmonary and COVID uses were. Mechanistic plausibility is not evidence of benefit; that is exactly the gap the aviptadil trials exposed.
Half-life, safety and the gray-market reality
Two practical problems compound the evidence gap. First, native VIP has a very short half-life — it is degraded within minutes in circulation — which is a large part of why turning it into a reliable drug has been so difficult and why the clinical programs used continuous IV infusion or specialized delivery rather than a convenience formulation. A self-administered nasal spray is not a validated way to achieve any particular exposure. Second, compounded nasal VIP is an unapproved product: it is not an FDA-approved drug for any indication, and there is no established long-term safety dataset for chronic self-dosing in otherwise-healthy people. This is the same structural problem we describe for other endogenous peptides sold ahead of their evidence, from LL-37 to thymosin alpha-1 and KPV: real biology, thin-to-absent human proof for the marketed use, and a product made outside the verified-content, verified-dose system. None of this is medical advice or a dosing endorsement.
The honest bottom line
VIP is a legitimate, well-studied human neuropeptide, and aviptadil is a real synthetic drug that earned serious clinical trials — which is more than most wellness peptides can say. But the pulmonary-hypertension signal was small and never confirmed,[3] the best COVID-19 trial was essentially negative,[5] and the intranasal “mold / CIRS” protocol that drives most consumer use has no controlled evidence at all. Respect the receptor biology; be skeptical of the spray bottle. On today’s evidence, VIP is a genuinely interesting molecule whose marketed use has outrun its proof.
Disclaimer: This article is general educational information about the science of vasoactive intestinal peptide and aviptadil. It is not medical advice, a diagnosis, or a recommendation to use any peptide or compounded product, and it is not a dosing guide. VIP/aviptadil is not an FDA-approved consumer product; talk to a qualified clinician before making any health decision.
